RBC Capital Markets maintained an "outperform" rating on Medtronic
after the medical device maker reported in-line results for the second quarter.
The Minneapolis-based company posted a profit of 54 cents per share on sales
of $2.765 billion. "By product category, the results were mixed, with some
products outperforming, while others came in slightly below expectations,"
wrote analyst Jennifer Hsui, in a note to investors. "Overall, however,
we think the positives outweighed the negatives, and the quarter again demonstrated
the benefit of a diverse product-portfolio."